Desmopressin stimulation test before and after pituitary surgery in patients with Cushing's disease
- PMID: 11453953
- DOI: 10.1046/j.1365-2265.2001.01324.x
Desmopressin stimulation test before and after pituitary surgery in patients with Cushing's disease
Abstract
Objective: The desmopressin test has been proposed as a useful tool for the differential diagnosis of Cushing's disease. The aim of our study was to investigate, in a large series of patients with Cushing's disease, the incidence of a positive ACTH and cortisol response to desmopressin. Moreover, we repeated the test soon after surgery to verify its usefulness in the assessment of early and late surgical results.
Patients and methods: One hundred and seven consecutive patients with Cushing's disease, 89 female and 18 male patients, with a mean age of 37.2 +/- 1.3 years, were studied. All patients, except three, repeated the test 5-6 days after surgery. Desmopressin (10 microg) was injected i.v. and blood samples were drawn 15, 30, 45 and 60 minutes thereafter. Plasma ACTH and serum cortisol were measured in duplicate by commercially available immunoassays. A positive response to desmopressin was considered to be a plasma ACTH and serum cortisol increment of at least 30% and 20% above baseline, respectively.
Results: Mean basal plasma ACTH level was 17.3 +/- 1.7 pmol/l and rose to a peak level of 42.7 +/- 4.9 pmol/l at 15 minutes Mean basal serum cortisol level was 574 +/- 19 nmol/l and rose to a peak level of 814 +/- 28 nmol/l at 45 minutes. ACTH and cortisol incremental changes were inversely correlated with their respective basal levels. Ninety patients (84.1%) had an ACTH and 84 patients (78.5%) had a cortisol response to desmopressin. Several clinical and demographic characteristics were not significantly different among desmopressin responders and non responders, except that basal ACTH and cortisol levels were significantly higher in desmopressin non responders (27.2 +/- 8.3 pmol/l, 781 +/- 86 nmol/l) than in desmopressin responders (15.4 +/- 1.2 pmol/l, 535 +/- 14 nmol/l). Disappearance of the ACTH and cortisol response to desmopressin after surgery occurred in 50 of 87 (57%) ACTH responders and in 57 of 81 (70.4%) cortisol responders, respectively. However, concordance between the desmopressin test and surgical outcome was not complete. Indeed, 18 patients considered in remission still showed an ACTH increase after desmopressin and, on the contrary, four patients with disappearance of the ACTH response had persistence of hypercortisolism. During follow-up monitoring, three patients, who had persistence of the ACTH response to desmopressin, relapsed 24, 38 and 54 months after surgery.
Conclusions: Desmopressin administration elicits a significant rise in ACTH and cortisol levels in the majority but not all patients with Cushing's disease. There is a good, but not complete, concordance between the response to the desmopressin test and the surgical outcome. Our preliminary data show that persistence of the ACTH response to desmopressin in the early postoperative period might be associated with a higher risk of late relapse.
Similar articles
-
Usefulness of the desmopressin test in the postoperative evaluation of patients with Cushing's disease.Eur J Endocrinol. 2000 Aug;143(2):227-34. doi: 10.1530/eje.0.1430227. Eur J Endocrinol. 2000. PMID: 10913942
-
Assessment of cortisol and ACTH responses to the desmopressin test in patients with Cushing's syndrome and simple obesity.Clin Endocrinol (Oxf). 1999 Oct;51(4):473-7. doi: 10.1046/j.1365-2265.1999.00830.x. Clin Endocrinol (Oxf). 1999. PMID: 10583315
-
Effect of desmopressin on ACTH and cortisol secretion in states of ACTH excess.Clin Endocrinol (Oxf). 1997 Jun;46(6):661-8. doi: 10.1046/j.1365-2265.1997.1330954.x. Clin Endocrinol (Oxf). 1997. PMID: 9274696
-
DIAGNOSIS OF ENDOCRINE DISEASE: The role of the desmopressin test in the diagnosis and follow-up of Cushing's syndrome.Eur J Endocrinol. 2018 May;178(5):R201-R214. doi: 10.1530/EJE-18-0007. Epub 2018 Feb 22. Eur J Endocrinol. 2018. PMID: 29472379 Review.
-
The conundrum of differentiating Cushing's syndrome from non-neoplastic hypercortisolism: a systematic review and meta-analysis.Pituitary. 2024 Aug;27(4):345-359. doi: 10.1007/s11102-024-01408-w. Epub 2024 Jun 18. Pituitary. 2024. PMID: 38888685
Cited by
-
Peri-operative management of Cushing's disease.Rev Endocr Metab Disord. 2010 Jun;11(2):127-34. doi: 10.1007/s11154-010-9140-6. Rev Endocr Metab Disord. 2010. PMID: 20556520 Review.
-
Recurrence of Cushing's disease preceded by the reappearance of ACTH and cortisol responses to desmopressin test.Pituitary. 2004;7(3):183-188. doi: 10.1007/s11102-005-0425-9. Pituitary. 2004. PMID: 16328567
-
The Treatment of Cushing's Disease.Endocr Rev. 2015 Aug;36(4):385-486. doi: 10.1210/er.2013-1048. Epub 2015 Jun 11. Endocr Rev. 2015. PMID: 26067718 Free PMC article. Review.
-
Duration of post-operative hypocortisolism predicts sustained remission after pituitary surgery for Cushing's disease.Endocr Connect. 2017 Nov;6(8):625-636. doi: 10.1530/EC-17-0175. Epub 2017 Sep 14. Endocr Connect. 2017. PMID: 28912338 Free PMC article.
-
Treatment challenges in pediatric Cushing's disease: Review of the literature with particular emphasis on predictive factors for the disease recurrence.Endocrine. 2019 Nov;66(2):125-136. doi: 10.1007/s12020-019-02036-2. Epub 2019 Nov 7. Endocrine. 2019. PMID: 31701434 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical